↑点击上面图片 加雪球核心交流群 ↑ 风险提示：本文所提到的观点仅代表个人的意见，所涉及标的不作推荐，据此买卖，风险自负。 作者： 炼金女王 1981年创立杜肯资本 （ Duquesne Capital ） ， 1986–2010 年对外管理资金期间 ， 实现年化复合回报率约30% ， 连续24年无年度亏损 。 1988–2000年兼任量子基金 （ Quantum Fund ） 首席投资经理 ， 1992年与索罗斯联手做空英镑一战成名 。 来源：雪球 今天看了一篇大摩对斯坦利 ・ 德鲁肯米勒 （ Stanley Druckenmiller ） 的访谈 ， 感触颇深 。 本文不拆解访谈细节 ， 只想借这位传奇投资者 之口 ， 说出一个残酷又真实的投资真相 。 德鲁肯米勒是谁 ？ 他是华尔街顶级宏观对冲基金经理 ， 也曾是索罗斯黄金搭档 。 1953年生于美国匹兹堡 ， 鲍登学院 （ Bowdoin College ） 英语与经济学双 学士 。 2010年后转为家族办公室 ， 聚焦集中成长 + 宏观择时 ， 重仓 AI 、 生物科技与资源板块 ， 长期业绩大幅跑赢市场 ， 是全球极少数能跨越多 轮周期 、 持续创 ...

以下文章来源于IN咖 ，作者聪明投资者 IN咖 . 多视角关注优秀投资人和企业家 1、我觉得 " 逆向思维 " 这件事被高估了。我确实喜欢那种情形：我有极强的确信，但几乎没有人相信我。那种不被理解，反而会让我更坚定。 2、我的优势不在于智商，而在于扣扳机。 3、你如果只盯着 "今天是什么"，基本赚不到钱。你得往前看 ， 什么可能改变？改变之后，投资者会怎么重新理解它？ 4、我在意拥挤，更多是为了找更好的进场点 。 它影响我怎么进，不太影响我做不做、也不太影响我对这笔交易的判断。 5、你不能让自己变成波动的受害者，你得 学会 利用它。 6、我这些年有个经验 ， 一旦真的出现那种巨大的、结构性的变化，投资者很难逼着自己 立刻 跟上，它会慢半拍、再慢半拍。 7、你回撤了，你难受了，你会怀疑自己 。 但你如果真的行，你最终得学会一件事：别在那儿反复咀嚼，过去就过去，往前走。 8、我很确定， AI在现实世界里最扎实、最可能跑出成果的应用场景之一，很可能就在生物科技 ， 药物发现、诊断、监测 ——基本整条链条都会用到。 9、从机会集的角度看， 接下来三到四年，我其实挺兴奋的 。宏观这门生意过去十到十五年几乎 "死"了，但 ...

Core Insights - The meeting between Jiangsu Province Governor Liu Xiaotao and Fosun International Chairman Guo Guangchang highlights the ongoing collaboration and investment opportunities in Jiangsu, focusing on sectors like biomedicine, healthcare, cultural tourism, consumption, and finance [1] Group 1: Investment and Economic Development - Fosun has invested over 100 billion yuan in Jiangsu, establishing a strong presence across multiple industries [2] - The company aims to deepen its business cooperation in Jiangsu, leveraging its technological and talent advantages to meet local development needs [1][2] Group 2: Biomedicine Sector - Fosun Pharma has developed a collaborative industrial ecosystem in Jiangsu, with multiple innovative drugs and biosimilars launched in the past five years [2] - The company plans to maintain its R&D investment during the 14th Five-Year Plan, focusing on areas such as metabolism, hematology, oncology, respiratory, autoimmune, and ophthalmology [2] Group 3: Cultural Tourism and Consumer Sector - The Taicang Alps International Resort, developed by Fosun Tourism, has become a benchmark for the "ice and snow economy" in the Yangtze River Delta, attracting over 2 million visitors since its opening in November 2023 [3] - The Club Med resort in Nanjing has also gained popularity since its opening in October 2023, while the Suzhou Songhelou restaurant is expanding internationally with plans to open its first overseas location in London by April 2025 [3] Group 4: Collaboration in Emerging Technologies - Fosun is engaging in extensive collaborations with various regions in Jiangsu through investment funds, focusing on cutting-edge fields such as embodied intelligence, semiconductors, and new materials [3]

Core Viewpoint - Newnow (300765) announced a change in its management, appointing Dai Long as the new General Manager while he also holds the positions of Board Secretary and Securities Affairs Representative [1][4] Management Changes - Dai Long, born in June 1992, has a background in finance and has been with Newnow since December 2016, serving in various roles including Financial Manager and Board Secretary [4] - Despite being appointed to a key position, Dai Long does not hold any shares in Newnow and has no connections with major shareholders or other executives [4] - Dai Long's total pre-tax compensation for 2024 is reported at 223,200 yuan, a decrease of 121,100 yuan from 2023 [4][6] Executive Compensation - Other executives at Newnow also experienced significant salary reductions in 2024, with Vice General Manager Liu Gang's compensation dropping to 188,800 yuan, a decline of 18.89% year-on-year [7] - The collective salary cuts among executives are linked to the company's poor performance [7] Financial Performance - In 2024, Newnow reported revenues of 1.981 billion yuan, a year-on-year decrease of 21.98%, and a net profit attributable to shareholders of 53.7263 million yuan, down 87.63% [7] - The company anticipates further losses in 2025, projecting a net profit attributable to shareholders between -255 million yuan and -170 million yuan [7] Business Overview - Newnow, a core subsidiary of CSPC Pharmaceutical Group, was established in 1989 and went public in 2019 [7] - It is the largest production base for chemical synthetic xanthine products globally, with key products including caffeine and theobromine [7] - The company has developed a dual-driven business model focusing on traditional functional foods and innovative biopharmaceuticals [8] Strategic Developments - Newnow's subsidiary, Jushi Biotech, signed a strategic cooperation agreement with AstraZeneca for eight innovative long-acting peptide drug projects, with AstraZeneca agreeing to pay a $1.2 billion upfront fee and up to $17.3 billion in milestone payments [8] - Newnow plans to list on the Hong Kong Stock Exchange to expand financing channels for innovative drug research and development [8] - The company increased its stake in Jushi Biotech to 80% by acquiring 29% of its shares for 1.1 billion yuan [8] Market Performance - As of January 30, Newnow's stock price closed at 38.87 yuan per share, reflecting a decline of 15.72%, with a total market capitalization of 54.6 billion yuan [9]

Investment Rating - The report does not explicitly provide an investment rating for the biosimilar industry in Europe. Core Insights - The report highlights the ongoing importance of biosimilars in the European healthcare system, emphasizing their role in cost savings for payers, creating space for innovation, and expanding patient access to biologics since the first biosimilar was launched in 2006 [5][11]. - It presents new observations regarding the market status in 2025 and a simplified set of key performance indicators (KPIs) to monitor the impact of biosimilars across 23 European markets [6][7]. - The report indicates that the biosimilar market is maturing, with growth rates aligning more closely with other segments of the pharmaceutical market, reflecting a growth rate of approximately 11% [12]. Summary by Sections Introduction - The report builds on previous publications and provides forward-looking insights into the opportunities and challenges facing the European biosimilar competition [4]. Pipeline - The analysis indicates that by 2032, around 100 biologics will lose exclusivity in Europe, with 79% currently lacking any biosimilar in development, leading to an increase in biosimilar gaps [26][28]. Commercial Attractiveness - Regulatory simplifications by the European Medicines Agency (EMA) are expected to reduce development costs and timelines for biosimilars, although they may not fully address existing biosimilar gaps [37][38]. International Competitiveness - Europe remains a leader in the biosimilar market, with a market size that is 55% larger than that of the U.S. and significantly exceeds that of China [50][51]. Access Inequality - There is a persistent disparity in access to biologics between Western and Eastern Europe, with patients in Western Europe receiving 35% more treatment days compared to those in Eastern Europe [59][64]. Advanced Planning - The report emphasizes the need for advanced indicators to support understanding of the future impacts of biosimilar competition, highlighting the importance of monitoring pipeline activities and market dynamics [25][28].

Core Viewpoint - The company has been actively implementing an internationalization strategy across various dimensions, including innovation research and development, licensing, production operations, and commercialization, to enhance operational efficiency and strengthen its global market presence [1] Group 1: International Market Strategy - The company has established a significant presence in overseas markets, primarily covering the United States, Europe, Africa, India, and Southeast Asia [1] - In the European Union market, the company employs a diversified sales model [1] Group 2: Pharmaceutical Sector - In the pharmaceutical sector, biosimilars are developed and produced in China, with distribution to the EU market through overseas partners [1] - The injectable business primarily operates on a B2B model, supplying EU customers from manufacturing bases in India and Europe [1] Group 3: Medical Devices Sector - In the medical devices sector, the company utilizes a combination of distribution and direct sales to cover the EU market [1]

Core Viewpoint - The commercialization of ADC (Antibody-Drug Conjugates) drugs is reaching a turning point, highlighting a capacity gap in the industry as WuXi AppTec (HK02268) announces a significant acquisition of Easton Biopharma (HK01875) to enhance its production capabilities [1][4]. Group 1: Acquisition Details - WuXi AppTec plans to acquire approximately 773 million shares of Easton Biopharma at a price of HKD 4.000 per share, valuing the total equity at approximately HKD 30.91 billion [2]. - The offer price represents a significant premium of about 99% over the closing price of HKD 2.010 per share on December 22, 2025, and a 114.67% premium over the 30-day average closing price of HKD 1.860 per share [2]. - Easton Biopharma has a limited market presence, often referred to as a "zombie stock," with a typical daily trading volume of less than HKD 1 million [2]. Group 2: Business Synergy - The acquisition is driven by the business synergy between WuXi AppTec and Easton Biopharma, as the latter is one of the earliest developers of ADC drugs in China, although it has faced challenges with its ADC pipeline [3]. - Easton Biopharma's revenue from product sales has been increasing, with projected revenues of RMB 3.04 billion, RMB 6.30 billion, and RMB 8.77 billion for 2022, 2023, and 2024 respectively, indicating a shift towards profitability in 2024 [3]. Group 3: Production Capacity and Strategic Fit - Easton Biopharma possesses a large-scale GMP-compliant production facility and has established an integrated ADC platform, which aligns with WuXi AppTec's strategy to enhance production capacity [4][5]. - The geographical proximity of both companies in the Yangtze River Delta region is crucial for reducing technology transfer risks and achieving operational efficiency [1][5]. - WuXi AppTec anticipates significant growth, projecting a revenue increase of over 45% and a gross profit increase of over 70% for 2025, alongside a substantial rise in adjusted net profit [6].

Group 1 - The core viewpoint of the news is that Baiotai's stock has shown a mixed performance in recent months, with a year-to-date increase of 21.93% but a decline of 21.13% over the past 60 days [2] - As of December 23, Baiotai's stock price was 23.63 yuan per share, with a market capitalization of 9.785 billion yuan and a trading volume of 816.40 million yuan [1] - The company has seen a net inflow of 794,500 yuan from major funds, with significant buying activity accounting for 15.09% of total trading [1] Group 2 - Baiotai's main business revenue composition includes 91.90% from drug sales, 6.55% from licensing, 0.90% from contract manufacturing, and 0.65% from technical services [2] - For the period from January to September 2025, Baiotai achieved an operating income of 684 million yuan, representing a year-on-year growth of 17.57%, while the net profit attributable to the parent company was -224 million yuan, reflecting a 38.72% increase [2] - As of September 30, 2025, the number of shareholders in Baiotai was 9,397, a decrease of 0.89% from the previous period, with an average of 44,065 circulating shares per person, an increase of 0.89% [2]

Summary of Key Points from Conference Call Records Industry Overview - The conference call discusses the **innovative drug industry** in China, focusing on the **2026 outlook** and the ongoing **internationalization** of Chinese pharmaceutical companies [1][3][5][8]. Core Insights and Arguments - **Healthcare Negotiations**: Ongoing negotiations in healthcare are emphasizing tumor drugs, with innovative drugs receiving support but at potentially lower price reductions. The average price reduction for drugs is stabilizing around **60%** [2][4]. - **Commercial Insurance Directory**: The establishment of a commercial insurance directory for innovative drugs provides a second payment pathway for high-value drugs, benefiting CAR-T and ADC therapies [1][2]. - **Internationalization Phase 2.0**: Chinese pharmaceutical companies are entering the **2.0 phase** of internationalization, with a **60%** year-on-year increase in business development transactions, totaling **$88.26 billion** [3][5]. - **Focus on Innovative Technologies**: Key areas of focus include **ADC**, **I/O (immunotherapy)**, and **small nucleic acids**. Notable products and data releases are anticipated in these fields [1][6][7]. - **GLP-1 Market Potential**: The GLP-1 market is expected to grow significantly, with major companies like Eli Lilly, Roche, and AstraZeneca set to release critical clinical data in cardiovascular, diabetes, and obesity sectors [1][7]. Additional Important Content - **Collective Procurement Policies**: The latest round of collective procurement has introduced new focus areas such as maintaining clinical stability and ensuring quality, with price reductions stabilizing [4]. - **CRO Industry Recovery**: The CRO industry is experiencing a recovery, with significant growth in biopharmaceutical investments, particularly in the CDMO sector, which is benefiting from strong commercial demand [9][10]. - **Upstream Supply Chain and Equipment**: The domestic upstream supply chain and pharmaceutical equipment sectors are seeing improvements in profitability due to increased localization and technological upgrades [13]. - **Research Reagents Market**: The demand for research reagents is strong, driven by increased funding for research, with domestic brands improving in quality and responsiveness [14]. - **Impact of Global Expansion**: Local companies are leveraging global expansion strategies to alleviate domestic price pressures and enhance their competitive positioning in the international market [15]. This summary encapsulates the key points discussed in the conference call, providing insights into the current state and future outlook of the innovative drug industry in China.

Group 1 - The Chinese government is supporting the high-quality development of innovative drugs by providing up to 10 million yuan in funding for eligible projects, including first-class innovative drugs, second-class improved new drugs, and biosimilars [1] - Chinese pharmaceutical companies are transitioning from raw material producers to innovative drug manufacturers, with their share in global drug research and development nearing 30%, while the share of US companies has decreased to approximately 48% [4] - The number of Chinese innovative drugs included in global conference abstracts has reached a record high this year, indicating a growing recognition of China's contributions to drug development [4] Group 2 - In the first half of this year, US and Chinese pharmaceutical companies completed 14 licensing deals worth $18.3 billion, highlighting increasing collaboration between the two markets [4] - The expiration of patents for blockbuster drugs before 2030 is creating opportunities for collaboration between US and Chinese pharmaceutical companies, as US firms need to replenish their drug development pipelines [4] - The high costs associated with drug development in the US present challenges, further opening the door for partnerships with Chinese companies [4]